Lornoxicam / Thiocolchicoside

Lornoxicam / Thiocolchicoside Brands in Kenya:

Locam-MR®, Laso Healthcare pvt ltd.
Oxifast MR®, West-Coast Pharmaceutical Works Ltd.

Lornoxicam / Thiocolchicoside in Kenya: Brands,Uses, Cost
Lornoxicam / Thiocolchicoside in Kenya

Mode Of action:

Like other NSAIDs, lornoxicam inhibits prostaglandin biosynthesis by blocking the enzyme cyclooxygenase.
Lornoxicam inhibits both isoforms in the same concentration range, that is, the ratio of COX-1 inhibition to COX-2 inhibition is 1:1.
It readily penetrates into the synovial fluid.
Thiocolchicoside is a muscle relaxant with anti-inflammatory and analgesic effects. It acts as a competitive GABAA receptor antagonist and also glycine receptor antagonist with similar potency and nicotinic acetylcholine receptors to a much lesser extent.


Inflammatory disease of the joints,Osteoarthritis,surgery,Sciatica and other inflammations.
As an adjuvant treatment in painful spasm associated with degenerative vertebral disorders,dorsal pain,lowback pain neurological disorder.


Absorption: Well absorbed orally,food delays absorption.
Distribution: 99% bound to plasma proteins
Metabolism: Metabolised to its inactive metabolite.
Elimination: Approximately 1/2 to 2/3 is eliminated via the liver and 1/3 to 42% via kidneys as 5-hydroxylornoxicam.
After oral administration,no thiocolchicoside is detected in plasma.
Only two metabolites are observed: The pharmacologically active metabolite SL 18.0740 and inactive metabolite SL59.0955.
For both metabolites ,maximum plasma concentration occur 1 hour after thiocolchicoside administration.
After a single oral dose of 8mg of thiocolchicoside the C max and AUC of SL 18.0740 are about 60ng/ml and 130 ng.h/ml respectively
After oral administration, thiocolchicoside is first metabolized in the aglycon 3-demethyltiocolchine. This step mainly occurs by intestinal metabolism explaining the lack of circulating unchanged thiocolchicoside by this route of administration.
After oral administration, thiocolchicoside is mainly excreted in faeces (79%) while urinary excretion represents only 20%.
No unchanged thiocolchicoside is excreted either in urine or faeces.


Gastrointestinal disorders (nausea and diarrhoea), Headache, Drowsiness, Anaphylactic reaction, Severe but seldom side effects include bleeding, bronchospasms and extremely rare Stevens-Johnson syndrome.

Reporting of suspected adverse reactions:

The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, pv@pharmacyboardkenya.org or clicking below button:


Use with caution in patients with active infections, Asthma, allergic disorders, Haemorrhagic disorders, Hypertension, Impaired renal, hepatic and cardiac function.
Lornoxicam should be taken with a meal to minimize gastrointestinal irritation
Use with caution in patients with diarrhoea.
Preclinical studies showed that one of the thiocolchicoside metabolites (SL59.0955)induced aneuploidy( i.e unequal number of chromosomes in dividing cells) at concentrations close to human exposure observed at doses 8mg twice daily.
Aneuploidy is considered as a risk factor for teratogenicity, embryo/foetal-toxicity, spontaneous abortion, and impaired male fertility and a potential factor for cancer.
As a precautionary measure, the use of the product at doses exceeding the recommended dose or long-term use should be avoided.
Patients should be carefully informed about the potential risk of a possible pregnancy and about effective contraception measures to be followed.



    • Vitamin K antagonists like warfarin increase the risk of bleeding.
    • Ciclosporin can lead to reduced kidney function, and to acute renal failure in rare cases
  • Lornoxicam can also increase the adverse effects of lithium, methotrexate and digoxin and its derivatives.
  • The effect of diuretics, ACE inhibitors and angiotensin II receptor antagonists can be reduced, but this is only relevant in patients with special risks like heart failure
  • Piroxicam, cimetidine can increase plasma levels


  • No known interactions with other drugs.


Contraindicated in patients with hypersensitivity to lornoxicam,Thiocolchicoside or any of the excipients.
Contraindicated in the condition of salicylate sensitivity,Gastrointestinal bleeding and bleeding disorders, Severe impairment of heart, liver or kidney function, in pregnancy and breast feeding women


8-16mg .Maximum daily dose is 24mg.

Lornoxicam / Thiocolchicoside in Kenya
Lornoxicam / Thiocolchicoside in Kenya
Lornoxicam / Thiocolchicoside in Kenya
Lornoxicam / Thiocolchicoside in Kenya

Clinical | Pharmacokinetic data

Pregnancy Category: Not Recommended
Routes of Administration: Oral
Bioavailability: Not Available
Protein Binding: Not Available
Metabolosim: Not Available
Onset of Action:
Elimination Half life: Not Available
Excretion: Not Available

Legal Status | Dosage forms & Strengths

Prescription Category:
Prescription only Medicine (POM) , ℞-only
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This drug is not a controlled substance under Narcotic Drugs and Psychotropic Substances (Control ) Act
Dosage Forms | Strengths:

Drug Indentifiers:

Refer to :

  • Lornoxicam
  • Thiocolchicoside

Drug Images

References/ Citation:

Side Effect

Suspected health product

At the time of the side effect, specify:

%d bloggers like this: